| This week's sponsor is Premier Research. | | | Can You Boost Your Odds in Early-Phase Oncology Trials? Find Out!
Despite advances in molecular targeting, developing new cancer drugs remains a long shot. Download our white paper for insights on maximizing early-phase trial success. Premier Research. It's what we do. Best. |
Today's Rundown House votes down right-to-try bill Auris’ tinnitus drug fails in phase 3 again Crinetics raises $63.5M for oral acromegaly therapy Flagship launches Foghorn Therapeutics with $50M investment FierceBiotech Radio: #FierceMadness and a peek into the drug-naming process Quest to shutter Michigan lab, let go of 57 workers in coming months #FierceMadness gets serious with 64 drug names, including play-in victors Taltz, Nerlynx Featured Story | | | Wednesday, March 14, 2018 The House of Representatives has rejected a bill that would have cut the FDA out of the process for clearing terminally ill patients to access experimental medicine. House Democrats voted overwhelmingly against the law, resulting in it falling just short of the required two-thirds majority. |
|
|
Top Stories Wednesday, March 14, 2018 Auris Medical’s tinnitus candidate Keyzilen has missed the primary endpoint in a phase 3 trial for the second time. The result wiped 37% off Auris’ already-depressed stock as its slim chance of salvaging the program faded. Wednesday, March 14, 2018 Perceptive leads a Series B round that will fund Crinetics' CRN00808 candidate through proof-of-concept studies as an alternative to injectable therapy for the disease. Wednesday, March 14, 2018 Foghorn Therapeutics seeks to unravel how chromatin regulation malfunctions and develop drugs to correct these problems and treat cancer. Wednesday, March 14, 2018 Fierce editors discuss this year's #FierceMadness drug-name tournament, while Brand Institute's Scott Piergrossi explains how drugs get their names. Wednesday, March 14, 2018 Quest Diagnostics, the New Jersey-based diagnostics maker, will close its Troy, Michigan, laboratory by early May, laying off 57 workers at the facility. Wednesday, March 14, 2018 After a bruising two-day play-in, we have our first round of winners in this year’s drug name tournament challenge. Symproic, Nerlynx, Taltz and Giapreza move into the round of 64 after defeating their opponents handily. Now it’s time to roll up your sleeves and vote your 32 picks. | This week's sponsor is Eurofins Advinus. | | | |
Resources Sponsored by: Reprints Desk The competitive landscape in medical device R&D is tough. And simply investing in R&D is no guarantee for profitability. So how do you accelerate time-to-market? Sponsored by: MK&A There’s no magic bullet to successful access but insights from patient advocates and industry experts can help shape future strategies. Learn how in this webinar. Sign up now! Sponsored by: RBC Wealth Management Employee stock option trading & administration, Restricted stock transactions (Rule 144), Affiliated trading plans (10b5-1), Directed share plans, Equity comp plan administration — private to public Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Presented by: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented by: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented by: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented by: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Drug Approval, Manufacturing Quality & Regulation 2018 | Online BioBasics: Biotech for the Non-Scientist March 29-30, 2018 | Boston, MA BioData World West Returns to San Francisco March 12-13 Understanding Drug Pricing and Reimbursement April 3,2018 | Washington, DC Field Service USA 2018 April 17-April 20, 2018 | JW Marriott Palm Desert Resort & Spa, CA
Drug Development Immersion April 25-26, 2018 | New York City Gene Therapy for Rare Disorders Summit April 30-May 2, 2018 | Boston, MA Biotech for the Non-Scientist May 2-3, 2018 | San Diego, CA MIXiii-Biomed 2018 May 15-17, 2018 | Tel-Aviv, Israel Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | Register and start preparing Today! | 